Personalis (NASDAQ:PSNL) Shares Gap Up - Here's Why

Key Points

• Personalis shares gapped higher, opening at $15.22 versus the prior close of $13.91, and last traded near $15.02 on volume of about 1.73 million shares.
• Analyst views remain mixed: the consensus rating is “Hold” with a $14.25 price target, while recent target changes ranged from $13.00 to $16.25.
• The company reported quarterly revenue of $22.36 million, above estimates, but missed on EPS with a loss of $0.30 versus the expected $0.26 loss. Insiders have sold roughly 435,000 shares worth $5.6 million over the past three months.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report)'s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $13.91, but opened at $15.22. Personalis shares last traded at $15.0180, with a volume of 1,726,099 shares traded.

Analyst Ratings Changes

PSNL has been the topic of several recent analyst reports. Lake Street Capital lowered shares of Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective on the stock. in a report on Monday, July 20th. BTIG Research boosted their target price on shares of Personalis from $11.00 to $16.25 and gave the company a "buy" rating in a report on Monday, July 20th. Wall Street Zen downgraded shares of Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, June 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Personalis in a report on Friday, July 17th. Finally, Morgan Stanley boosted their price objective on shares of Personalis from $9.00 to $13.00 and gave the company an "equal weight" rating in a research note on Thursday, July 9th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $14.25.

Personalis Price Performance

The firm has a 50-day simple moving average of $12.85 and a 200 day simple moving average of $9.53. The company has a market capitalization of $1.62 billion, a PE ratio of -14.22 and a beta of 2.27.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.04). The company had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Equities research analysts expect that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the completion of the transaction, the chief financial officer owned 198,833 shares of the company's stock, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm's stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the sale, the chief executive officer owned 235,986 shares of the company's stock, valued at approximately $3,103,215.90. This trade represents a 29.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 435,032 shares of company stock worth $5,599,929. Corporate insiders own 4.20% of the company's stock.

Hedge Funds Weigh In On Personalis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada increased its stake in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after buying an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its holdings in Personalis by 75.6% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company's stock worth $269,000 after acquiring an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Personalis by 55.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock worth $998,000 after acquiring an additional 101,706 shares in the last quarter. Focus Partners Wealth bought a new stake in shares of Personalis in the 1st quarter worth about $47,000. Finally, JPMorgan Chase & Co. increased its position in shares of Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company's stock worth $193,000 after purchasing an additional 24,621 shares during the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc NASDAQ: PSNL is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source